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Dr Antonio Giordano is interested in the molecular mechanisms and biochemical functions of proteins involved in the rate of cellular growth and division. Owing to the emerging appreciation of the cell cycle as a key to the control of cell proliferation and abnormal cell growth, Dr Giordano's research has important implications for the study of cancer. His early research includes seminal work demonstrating the importance of cell cycle proteins in the functioning of DNA tumor viruses. The transforming gene products of these viruses, such as the E1A oncoproteins of adenovirus 5, helped him in the identification of cellular factor p60, later shown by others to be cyclin A. This research led to the first demonstration, in 1989, of a physical link between cellular transformation and the cell cycle, thereby paving the way for the melding of these two areas of research. It also helped to open a very exciting avenue of research involving investigators with expertise in different aspects of growth control and cancer.
In collaboration with other groups, he identified the shift in the timing of activation of the three major mammalian cell cycle complexes involved in different cell cycle phases: cyclin E/cdk2, p60/cyclinA/cdc2/cdk2 and cyclin B/cdc2. Dr Giordano has made significant progress in his quest to identify novel factors involved in controlling cell growth. Through these efforts, he and his group first identified one of the members of the RB family, pRb2/ p130. His seminal contributions regarding this protein include the fundamental characterization of its function. His recent studies demonstrate that pRb2/pl30 is able to halt the proliferation of aggressive tumor cell lines both in vivo and in vitro. In addition, he has demonstrated that pRb2/p130 can function as a bona fide tumorsuppressor gene, mutated or inactivated in several cancers. His latest work focuses on developing different therapeutic delivery systems for pRb2/p130, with the goal of inhibiting tumor growth in vivo. This places pRb2/p130 as an emerging candidate for gene therapy in humans.
Dr Giordano's research has also led to the identification of two novel kinases, Cdk9 (PITALRE) and Cdk10 (PISSLRE). For this and other work, Dr Giordano is receiving growing recognition for his expertise in the area of cell cycle regulation and oncogenesis.
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